Anthony Lawlor (Kildare North, Fine Gael)
Link to this: Individually | In context

Question 159: To ask the Minister for Health further to Parliamentary Question No. 620 of 12 June 2012 when the assessment for the availability of resources to provide for the long term treatment with Pradaxa for the prevention of stroke in patients with atrial fibriliation will be completed; and if he will make a statement on the matter. [29892/12]

Róisín Shortall (Dublin North West, Labour)
Link to this: Individually | In context

Pradaxa is available under the GMS Scheme, the Drug Payment Scheme and other community drugs schemes for the prevention of blood clots in adult patients who have undergone elective hip replacement surgery or elective knee replacement surgery. The HSE is assessing the availability of resources to provide for the long term treatment with Pradaxa for the prevention of stroke in patients with atrial fibrillation. This is a complicated process with long term implications.

The HSE wrote to all GMS doctors and community pharmacy contractors in November 2011 to clarify the position in relation to Pradaxa. The HSE will continue to update healthcare professionals in relation to the matter. The HSE does not intend to disturb established therapeutic regimens for patients whose treatment with Pradaxa for the prevention of stroke was initiated prior to the clarification. The HSE hopes to finalise the assessment process as soon as possible.